相似文献
1
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
Clin Infect Dis. 2010 May 1;50(9):1258-67. doi: 10.1086/651603.
2
Recent advances in the prevention and treatment of respiratory syncytial virus disease.
J Gen Virol. 2025 Apr;106(4). doi: 10.1099/jgv.0.002095.
3
New strategies for control of respiratory syncytial virus infection.
Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245.
4
Respiratory syncytial virus: prospects for new and emerging therapeutics.
Expert Rev Respir Med. 2017 Aug;11(8):609-615. doi: 10.1080/17476348.2017.1338567. Epub 2017 Jun 14.
5
Targeting RSV with vaccines and small molecule drugs.
Infect Disord Drug Targets. 2012 Apr;12(2):110-28. doi: 10.2174/187152612800100143.
6
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
7
A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.
J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S103-S109. doi: 10.1093/jpids/piae027.
8
Preventive and therapeutic strategies for respiratory syncytial virus infection.
Curr Opin Pharmacol. 2001 Oct;1(5):497-503. doi: 10.1016/s1471-4892(01)00087-x.
9
New Approaches to Respiratory Syncytial Virus Prevention and Treatment.
Annu Rev Med. 2025 Jan;76(1):13-28. doi: 10.1146/annurev-med-061323-073934. Epub 2025 Jan 16.
10
Up-to-date role of biologics in the management of respiratory syncytial virus.
Expert Opin Biol Ther. 2020 Sep;20(9):1073-1082. doi: 10.1080/14712598.2020.1753696. Epub 2020 Apr 17.
引用本文的文献
1
Advances in development of antiviral strategies against respiratory syncytial virus.
Acta Pharm Sin B. 2025 Apr;15(4):1752-1772. doi: 10.1016/j.apsb.2025.02.015. Epub 2025 Feb 20.
2
Trend of pathogens and respiratory co-infections in the province of Messina: from pediatric age to senescence.
J Prev Med Hyg. 2024 Oct 31;65(3):E344-E355. doi: 10.15167/2421-4248/jpmh2024.65.3.3344. eCollection 2024 Sep.
3
Respiratory Syncytial Virus Infection in Older Adults: An Update.
Drugs Aging. 2024 Jun;41(6):487-505. doi: 10.1007/s40266-024-01118-9. Epub 2024 May 7.
4
Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.
In Silico Pharmacol. 2023 Dec 24;12(1):5. doi: 10.1007/s40203-023-00178-w. eCollection 2024.
5
Respiratory Syncytial Virus Infection: Treatments and Clinical Management.
Vaccines (Basel). 2023 Feb 20;11(2):491. doi: 10.3390/vaccines11020491.
6
The Maresin 1-LGR6 axis decreases respiratory syncytial virus-induced lung inflammation.
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2206480120. doi: 10.1073/pnas.2206480120. Epub 2023 Jan 3.
7
Clinical and biological consequences of respiratory syncytial virus genetic diversity.
Ther Adv Infect Dis. 2022 Oct 8;9:20499361221128091. doi: 10.1177/20499361221128091. eCollection 2022 Jan-Dec.
8
Immunoinformatics-Aided Analysis of RSV Fusion and Attachment Glycoproteins to Design a Potent Multi-Epitope Vaccine.
Vaccines (Basel). 2022 Aug 24;10(9):1381. doi: 10.3390/vaccines10091381.
9
The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2598-2604. doi: 10.1080/14756366.2022.2123804.
10
RSV-associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomes.
Health Sci Rep. 2022 Apr 14;5(3):e556. doi: 10.1002/hsr2.556. eCollection 2022 May.
本文引用的文献
1
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.
2
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
BMC Infect Dis. 2009 Jul 5;9:106. doi: 10.1186/1471-2334-9-106.
3
Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.
Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
4
Challenges in developing a pediatric RSV vaccine.
Hum Vaccin. 2009 Sep;5(9):582-91. doi: 10.4161/hv.9131. Epub 2009 Sep 28.
5
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
J Infect Dis. 2009 Aug 1;200(3):439-47. doi: 10.1086/600108.
6
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.
Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62. doi: 10.1128/AAC.00014-09. Epub 2009 Jun 8.
7
Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus.
Clin Vaccine Immunol. 2009 Jun;16(6):859-65. doi: 10.1128/CVI.00033-09. Epub 2009 Apr 15.
8
Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
Curr Opin Mol Ther. 2009 Apr;11(2):208-18.
9
The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism.
J Virol. 2009 Jun;83(11):5353-62. doi: 10.1128/JVI.02374-08. Epub 2009 Mar 18.
10
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.
J Gen Virol. 2009 May;90(Pt 5):1119-1123. doi: 10.1099/vir.0.009308-0. Epub 2009 Mar 4.
Zotero 插件